Does the relationship between the pharmaceutical industry and healthcare professionals need to change?
We have made a number of changes to how we interact with healthcare professionals (HCPs), including how we incentivise our pharmaceutical sales representatives, how we support medical education and stopping payments to external HCPs to speak on our behalf about our prescription medicines.
In all of our interactions with HCPs we aim to be transparent about our work, operate with integrity, and always put the interests of patients first.
We’ve made these changes because we believe the established way of operating is outdated and doesn’t work effectively for patients, HCPs or the pharmaceutical industry.
These changes are significant but we are committed to transforming our business model so that patients are at the heart of every decision we take
We realise that there are a lot of different views about the relationship between pharmaceutical companies and HCPs. We have interviewed a number of leading industry experts to get their perspectives on this topic.
Paul Simms has been Chairman of Eyeforpharma since 2009. He has a special interest in new projects and innovation in the pharmaceutical industry. In a recent white paper, eyeforpharma speaks to the experts, both GSK insiders and outside observers, asking the fundamental questions: Will GSK’s new ‘ethical’ approach to its customers deliver commercial success?
Dr Virginia Acha:
Executive Director, Research, Medical and Innovation Policy, ABPI and has responsibility for driving the agenda for innovation in the UK. Dr Acha entered the pharmaceutical industry after a decade in academia.
Dr Martin Makary:
Professor of Surgery at Johns Hopkins University and professor of health policy and management at the Johns Hopkins Bloomberg School of Public Health. Dr. Makary is a fellow of the American College of Surgeons. He served in leadership roles at the United Nations’ World Health Organization Safe Surgery Saves Lives Initiative.
Professor Sir Michael Rawlins:
Chair of the UK Medicines and Healthcare Products Regulatory Agency as well as Chairman of Biobank. Prior to this he was Chair of the UK National Institute for Health and Care Excellence (NICE) from 1999 to 2013.
Secretary General for the European Patients Forum an umbrella organisation that works with patient groups in public health and health advocacy across Europe.
CEO of MedTech Europe, EDMA and Eucomed. In 2015, Eucomed and EDMA members adopted a new code that regulates all aspects of the industry’s relationship with healthcare professionals and healthcare organisations.
Putting the patient first by addressing industry practices – Panel discussion at the 2016 WHA.
Chair: Dr. Jean F. Freymond, President, Dialogues Geneva (D@G) and Network for Governance, Entrepreneurship & Development (GE&D), Geneva, Switzerland. Panellists: Danie du Plessis, Senior Vice President, Head of Worldwide Medical Affairs (GSK); Dr Matthias Wienold, International Alliance of Patients’ Organisations (IAPO); Dr Julia Tainijoki-Seyer, World Medical Association; Sophie Peresson, Transparency International.
How we do business
How we do business
Find out how we will be publicly disclosing information on payments and transfers of value that we make to doctors and other healthcare professionals (HCPs).